Company Overview
MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, Europe, and internationally. The company's testing solutions include Confirm mdx for prostate cancer tissue test that validates epigenetic test that guides the detection of occult prostate cancer on a patient's previously biopsied negative tissue; ExoD, a non-invasive urine test to assess risk of having clinically prostate cancer; and Resolve mdx for urinary tract infection that identifies personalized effective antibiotic options against the patient's infection. It offers genomic prostate score, which provides personalized genomic insights to physicians and patients navigating the complexities of prostate cancer diagnosis and treatment. The company sells its products through urology sales force consisting of direct sales representatives, strategic account managers, and regional sales managers. The company has a collaboration the initiation of Genomic Prostate Score (GPS) testing. The company was formerly known as OncoMethylome Sciences SA and changed its name to MDxHealth SA in October 2010. MDxHealth SA was incorporated in 2003 and is headquartered in Herstal, Belgium.
Why Investors Should Care
Revenue has grown at a 42.8% CAGR over the past five years.
Recent Developments
- Dec 2025 Revenue of $107.88M (+19.8% YoY); net profit $-33.52M.
- Trailing 12 Months Year-on-year growth — revenue +2.3%.
- 5-Year Trend Long-term compounding — revenue CAGR 42.8%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 42.79% |
| 1 Year: | 2.30% |
Stock Price Performance
| 1 Year: | -74.05% |
| 6 Months: | -78.89% |
| 3 Months: | +30.68% |
| 1 Month: | +54.77% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMABelow
- RSI (14)56.99 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 42.8% over 5 years.
CONS
- Trading 85.7% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | MDXH MDxHealth SA PHARMA | 0.71 | -1.00 | $67.75M | 0.00% | -15.62% | - | 42.79% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Revenue | - | 24.29M | 26.61M | 27.43M | 29.55M | 27.39M |
| Cost of Revenue | - | 8.79M | 9.04M | 9.56M | 10.86M | 10.77M |
| Gross Profit | - | 15.50M | 17.57M | 17.88M | 18.69M | 16.61M |
| Operating Expenses | - | 20.09M | 19.48M | 20.52M | 24.91M | 23.92M |
| Operating Income | - | -4.59M | -1.92M | -2.64M | -6.22M | -7.30M |
| EBITDA | - | -1.65M | 770.00K | 114.00K | -11.99M | 2.47M |
| Interest Expense | - | 5.18M | 6.29M | 5.88M | -5.49M | 8.95M |
| Pretax Income | - | -9.07M | -7.79M | -8.02M | -10.50M | -8.87M |
| Tax Provision | - | 137.00K | -416.00K | -6.00K | -1.57M | 0 |
| Net Income | - | -9.21M | -7.37M | -8.01M | -8.93M | -8.87M |
| Diluted EPS | -0.14 | -0.19 | - | -0.16 | -0.17 | -0.17 |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Revenue | - | 37.05M | 70.19M | 90.05M | 107.88M |
| Cost of Revenue | - | 17.84M | 26.26M | 34.91M | 38.24M |
| Gross Profit | - | 19.22M | 43.93M | 55.14M | 69.63M |
| Operating Expenses | - | 57.63M | 70.67M | 79.17M | 85.00M |
| Operating Income | - | -38.41M | -26.74M | -24.03M | -15.37M |
| EBITDA | - | -36.50M | -30.66M | -22.02M | -14.55M |
| Interest Expense | - | 2.64M | 5.58M | 7.63M | 11.62M |
| Pretax Income | - | -44.04M | -43.10M | -37.69M | -35.38M |
| Tax Provision | - | 0 | 1.00K | 382.00K | -1.86M |
| Net Income | - | -44.04M | -43.10M | -38.07M | -33.52M |
| Diluted EPS | - | -2.80 | -1.66 | -1.16 | -0.67 |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Total Assets | - | 119.14M | 129.13M | 157.33M | 147.95M |
| Current Assets | - | 29.15M | 38.16M | 66.89M | 53.41M |
| Cash & Equivalents | - | 15.50M | 22.38M | 46.80M | 29.03M |
| Inventory | - | 2.33M | 2.78M | 3.87M | 6.74M |
| Receivables | - | 9.36M | 11.09M | 14.44M | 14.68M |
| Total Liabilities | - | 109.82M | 121.92M | 142.49M | 160.05M |
| Current Liabilities | - | 18.28M | 19.52M | 42.66M | 49.53M |
| Long Term Debt | - | 34.91M | 35.56M | 50.97M | 76.20M |
| Total Debt | - | 39.79M | 41.27M | 60.06M | 86.60M |
| Total Equity | - | 9.31M | 7.21M | 14.84M | -12.09M |
| Shares Outstanding | - | 16.29M | 27.29M | 49.50M | 51.36M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | -34.12M | -21.50M | -18.53M | -2.19M |
| Investing Cash Flow | - | -29.04M | -3.93M | -1.64M | -18.56M |
| Financing Cash Flow | - | 20.72M | 32.28M | 44.60M | 2.96M |
| Capital Expenditure | - | -4.16M | -5.02M | -2.16M | -1.16M |
| Free Cash Flow | - | -38.28M | -26.52M | -20.69M | -3.35M |
| Net Change in Cash | - | -42.44M | 6.85M | 24.43M | -17.78M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Gross Margin % | - | 51.9% | 62.6% | 61.2% | 64.5% |
| Operating Margin % | - | -103.7% | -38.1% | -26.7% | -14.2% |
| Net Margin % | - | -118.9% | -61.4% | -42.3% | -31.1% |
| ROE % | - | -472.8% | -597.9% | -256.5% | 277.2% |
| ROCE % | - | -38.1% | -24.4% | -21.0% | -15.6% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Bleichroeder LP | 27.04% | 7.38M | $4.65M |
| 2 | MVM Partners, LLC | 17.23% | 4.70M | $2.96M |
| 3 | Perkins Capital Management, Inc. | 5.17% | 1.41M | $889.49K |
| 4 | Citadel Advisors Llc | 1.87% | 509.67K | $321.09K |
| 5 | Jane Street Group, LLC | 1.84% | 503.22K | $317.03K |
| 6 | GSA Capital Partners LLP | 1.77% | 481.99K | $303.65K |
| 7 | Renaissance Technologies, LLC | 1.19% | 325.08K | $204.80K |
| 8 | Millennium Management Llc | 0.84% | 228.51K | $143.96K |
| 9 | Squarepoint Ops LLC | 0.73% | 200.28K | $126.18K |
| 10 | Xtx Topco Ltd | 0.71% | 195.04K | $122.87K |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for MDXH
MDxHealth (MDXH) Stock Sees Fair Value Cut As Analysts Weigh Dilution And Execution - finance.yahoo.com
<a href="https://news.google.com/rss/articles/CBMimwFBVV95cUxPSklRem9tUnJpOHlJb3FKVjBralpnM3pUQ1k4a09fSUgyUmYxa3NJdWhrWWk0TzZLUVktdXNNMUtQWDJRdWpCa0YwQ196SkZ3bm5RNnNvanhoc2xnTVFYVXlhdF9YQWpMbEpwNFNHak9iaTFNMFhMamE3YURUSFFMNnoxWWJMN3VzaDBwMV…
Mdxhealth Sells 44M Shares for $20M Gross as Q2 Net Loss Hits $9.5M - Stock Titan
<a href="https://news.google.com/rss/articles/CBMipAFBVV95cUxQaTEwZE1NSmMwQ1RZRWxPTkdfN2V3VGd4ZHI4Q1FVTUVrNlZnUzN1aTM5dTRRZW1IT2pwWFJKay1lQ2RSSU04bDl4NUlXMXFDZ2I2UE1pWkZtU19RWng3bS05NzRLNzA1Ul9IUVp6MVZfbGI0dEdmNTRNX0VKc0hwWFcwLWZRN1poclViV0…
Why MDxHealth (MDXH) Stock Is Up Today - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMigAFBVV95cUxQR2l6WFRVM0tIWXZaQnBLMWxkaE9GWndRRDRHZ2R3WFJIUnZyUVV3QzUzSUZiV29WSmFaVF9ZVE51eGtUUDBSMzRoZnpWUXMzSWVMMnphX0hiaUZKUnA2RlJQY2x4by1NMGN0OXNMRDMwb053U1huX1RNWXkzLUM4cQ?oc=5" target="_…
BTIG cuts MDxHealth stock price target on higher share count - Investing.com
<a href="https://news.google.com/rss/articles/CBMivAFBVV95cUxNUjRwcVN2ajI0RW5ZZzhlSkQ2djg4QlJMV0did0lUVHNDNWZ6SGJCRzZabERHQlNvaFdXNFkwcXlTNXl0VkVoS0Mzd0tMR2xpcXJGUjlVQjZSZmR6Tmk1UV9aWFZBbGJTcjFBVlh1Q3p0TXdCcElRMzI1Z296a0VpODd6NHYtX0R4ZWtJY0…
MDXH Forecast — Price Target — Prediction for 2027 - tradingview.com
<a href="https://news.google.com/rss/articles/CBMiekFVX3lxTFA5LU5YWjZtWFJIM0xjZDJ0YnpVYU5neFVIeHlURDdYcnhuT25idktkNFBYVGRzYVlvdWNsTGViN0dYNk9JeUxVV1VnVC1kRWJacGVxS21ydWZQb2UyN1RjZWdqcTI3U3Fna1BEcDJYVnZVd3JoS0lpX0VB?oc=5" target="_blank">MDX…
MDXH - Finviz
<a href="https://news.google.com/rss/articles/CBMiRkFVX3lxTE9fRFZKSHNKUkNFZ2t3ZFNCTTFJVUJCdTZFWXNGcHk5c3hFYlk3VGprZXY5UG80V3FOdFhDQjJjaDVEU2VpX1E?oc=5" target="_blank">MDXH</a> <font color="#6f6f6f">Finviz</font>…
MDXH — Frequently Asked Questions
What is the current share price of MDxHealth SA (MDXH)?
As of 2026-09-19 21:16 PDT, MDxHealth SA (MDXH) trades at $0.71 on NasdaqCM. Its 52-week range is $0.40 to $5.00.
What is the market capitalisation of MDXH?
MDxHealth SA (MDXH) has a market capitalisation of $67.75M on NasdaqCM.
What is the P/E ratio of MDXH?
MDXH trades at a trailing price-to-earnings (P/E) ratio of -1.00. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is -1.06.
Is MDXH a good stock to buy?
This page provides a data-driven analysis of MDxHealth SA (MDXH), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.